India API market forecast to hit $12 billion by 2035

India’s active pharmaceutical ingredients market is projected to grow from $8.33 billion in 2025 to $12.0 billion by 2035, according to Market Research Future. The forecast points to steady demand for generic drugs, government support for domestic manufacturing, and broader adoption of more efficient production technologies.

Why it matters: - India’s API market is becoming a bigger piece of the global drug supply chain as demand rises for affordable generic ingredients and biopharmaceutical inputs. - The market’s projected growth signals more investment in domestic capacity, export-oriented manufacturing, and technology upgrades across the industry. - India remains a major supplier, covering nearly 20% of global generic medicines by volume and more than 50% of worldwide vaccine demand.

What happened: - Market Research Future valued the India Active Pharmaceutical Ingredients market at $8.0 billion in 2024. - The firm projects the market will rise to $8.33 billion in 2025 and reach $12.0 billion by 2035. - The forecast implies a 3.76% compound annual growth rate for 2025 through 2035. - The report was published from New York and California on Aug. 21, 2026. - Market Research Future offered a free sample and customization request for the study.

The details: - Generic drug demand is the main growth driver, as patent expirations continue to create space for lower-cost alternatives. - India’s biopharmaceutical sector is expanding demand for complex synthetic and biotech-derived API molecules. - Government support through Production Linked Incentive schemes, bulk drug parks and domestic production policies is intended to strengthen self-reliance and reduce raw material imports. - Continuous flow chemistry, automation and digital monitoring are improving manufacturing efficiency and lowering costs. - Green chemistry and sustainable manufacturing practices are helping producers meet international environmental and quality standards. - Merchant API remains the leading business model because third-party suppliers serve domestic and global pharmaceutical companies. - Captive API production remains important for vertically integrated drugmakers that make ingredients for internal use. - Synthetic APIs account for most production, while biotech APIs are the fastest-growing synthesis category. - Generic APIs remain the main revenue source, while branded APIs serve proprietary and specialty drugs. - Cardiology is the largest application area, with oncology, pulmonology and neurology also showing strong demand. - Western India, including Gujarat and Maharashtra, remains the primary manufacturing hub. - Southern India, including Telangana, Andhra Pradesh and Karnataka, is a major center for R&D, biotechnology APIs and contract research. - Northern and central India are expanding manufacturing through fiscal incentives and infrastructure development. - The competitive field includes Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Divi's Laboratories, Lupin Limited, Aurobindo Pharma, Laurus Labs and Granules India.

Between the lines: - The forecast suggests India is moving beyond volume manufacturing toward more complex, higher-value API production. - Continuous chemistry, real-time analytics and automated plants point to a sector trying to cut costs while meeting tighter global compliance expectations. - The emphasis on HPAPIs, biologics and green manufacturing indicates a shift toward specialized capabilities rather than only scale. - The report’s focus on export strength shows the industry is still closely tied to demand outside India, not just domestic consumption.

What's next: - By 2035, the API market is expected to tilt further toward high-value molecules and automated production setups. - Expanded use of continuous chemistry and real-time analytical tools should improve output efficiency and regulatory compliance. - Growth in biopharmaceuticals, HPAPIs and sustainable manufacturing is likely to push Indian suppliers further up the value chain. - Continued government investment and trade support are expected to reinforce India’s role as a global API supplier.

The bottom line: - India’s API industry is set for steady but meaningful growth, with the biggest gains likely to come from generic drugs, complex molecules and technology-led manufacturing upgrades.